510(k) Report

510(k) · Cleared

Cleared

BD Probetec Chlamydia Trachomatis (CT) QX Amplified Dna Assay

K140446510(k) TraditionalCleared May 20, 201488-day reviewClass I21 CFR 866.3120

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Becton, Dickinson & CO · MKZ Dna Probe, Nucleic Acid Amplification, Chlamydia

Cleared on May 20, 2014 as substantially equivalent to K081824 (Becton, Dickinson & CO, 2008) after an 88-day review. Its family tree reaches back 2 generations to 1999.

Decided
May 20, 2014
Review
88 days
Class
Class I
Product code
MKZ
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K984631 (1999). 3 ancestors in all. No later device cites it as a predicate yet.

  1. Root · 2 generations backK984631 Bdprobetec ET Chlamydia Trachomatis and Neisseria Gonorrhoeae…Becton Dickinson Microbiology Systems · 1999 · Recalled
  2. 1 generation backK081824 BD Probetec Chlamydia Trachomatis (CT) Q Amplified Dna AssayBecton, Dickinson & CO · 2008
  3. This deviceK140446 BD Probetec Chlamydia Trachomatis (CT) QX Amplified Dna AssayBecton, Dickinson & CO · 2014
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K984631Bdprobetec ET Chlamydia Trachomatis and Neisseria Gonorrhoeae Amplified Dna…Becton Dickinson Microbiology Systems19992
−1K081824BD Probetec Chlamydia Trachomatis (CT) Q Amplified Dna AssayBecton, Dickinson & CO2008—
0 (this device)K140446BD Probetec Chlamydia Trachomatis (CT) QX Amplified Dna AssayBecton, Dickinson & CO2014—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
200110
FIG. 1 — Lineage of K140446, 1999–2014Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in MKZ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new MKZ device

  1. #1 K230451 Aptima® Chlamydia trachomatis Assayscore 6.4 · 1 generation · no Class I recall
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K081824BD Probetec Chlamydia Trachomatis (CT) Q Amplified Dna Assay
Summary page 1
…ce The BD ProbeTec Chiamydia trachomatis (CT) Q" Amplified DNA Assay (RD ProbeTec CTQ Assay) was cleared for use with the predicate BD Viper System in extracted mode via K08 1824. DeieDscrintion The RD ProbeTec CTQ Assay is based on the simultaneous amplification and detection of target DNA using ampl…
Becton, Dickinson & CO2008—

Also cleared against K081824: 2 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 15 years and passes through 2 companies; a new generation was cleared every 9.1 years on median.
  • 2 of the 3 ancestors have a recall of any class.
  • 2 other devices also cite its predicate K081824.

How does its category compare?

All MKZ devices

MKZ Dna Probe, Nucleic Acid Amplification, Chlamydia: FDA decisions, review times, recalls and adverse event reports over 20 years. 2014, this device’s year, is highlighted.

FDA decisions per year · MKZ

1in 2023

2007: 22008: 22009: 22012: 12014: 12023: 1
2007high 2 (2007) · low 0 (2010)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · MKZ

Too few MKZ 510(k)s in any year since 2007 to give a median.

Recalls per year · MKZ

1in 2010

2009: 12010: 1
2007high 1 (2009) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · MKZ

1in 2025

2010: 12011: 92012: 12013: 62014: 22015: 12016: 12017: 62018: 32019: 32020: 72021: 92022: 22023: 42024: 72025: 1
2007high 9 (2011) · low 0 (2007)2025

MAUDE reports naming product code MKZ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—00
20082—00
20092—10
20100—11
20110—09
20121—01
20130—06
20141—02
20150—01
20160—01
20170—06
20180—03
20190—03
20200—07
20210—09
20220—02
20231—04
20240—07
20250—01
20260—0—

What is it indicated for?

The BD Probe Tec Chiamydia trachomatis (CT) QX Amplified DNA Assay, when tested with either the BID ViperM System In Extracted Mode or the BD Vipertm LT System, uses Strand Displacement Amplification technology for the direct, qualitative detection of Chiamydia trachomatis DNA in clinician-collected female endocervical and male urethral swab specimens, patient-collected vaginal swab specimens (in a clinical setting), and male and female urine specimens…

Read the full statement (127 words)

The BD Probe Tec Chiamydia trachomatis (CT) QX Amplified DNA Assay, when tested with either the BID ViperM System In Extracted Mode or the BD Vipertm LT System, uses Strand Displacement Amplification technology for the direct, qualitative detection of Chiamydia trachomatis DNA in clinician-collected female endocervical and male urethral swab specimens, patient-collected vaginal swab specimens (in a clinical setting), and male and female urine specimens (both UPT and Neat). The assay is also intended for use with gynecological specimens collected in BD SurePathm Preservative Fluid or PreservCytwm Solution using an aliquot that is removed prior to processing for either the BD SurePath or ThinPrep Tm Pap test. The assay is indicated for use with asymptomatic and symptomatic individuals to aid in the diagnosis of chlamydlial urogenital disease.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K140446: BD Probetec Chlamydia Trachomatis (CT) QX Amplified Dna Assay.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K140446

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026